Amylyx Pharmaceuticals
Developing avexitide-led therapies for endocrine and neurodegenerative diseases.
$34.85
After-hours close+0.12 (+0.35%)
At close$34.73(−6.59%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.38 | — | — |
| Aug 2026 | −$0.36 | −$0.39 | −8.1% |
| May 2026 | −$0.34 | −$0.37 | −8.8% |
| Mar 2026 | −$0.31 | −$0.30 | +3.2% |
| Nov 2025 | −$0.43 | −$0.37 | +14.0% |
The latest year is open to everyone — the 19 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Jan 2022 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.38 | — | — | $59.4K | — | — |
| Aug 6, 2026 | −$0.36 | −$0.39 | −8.1% | — | — | — |
| May 7, 2026 | −$0.34 | −$0.37 | −8.8% | — | — | — |
| Mar 3, 2026 | −$0.31 | −$0.30 | +3.2% | −$52.0K | — | — |
| Nov 6, 2025 | −$0.43 | −$0.37 | +14.0% | $52.0K | — | — |
The latest year is open to everyone — the 19 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 4, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 9, 2024 | ||||||
| Feb 22, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 13, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 12, 2022 | ||||||
| Mar 30, 2022 | ||||||
| Jan 10, 2022 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||